UBS Group
MBX

UBS Group’s MBX Biosciences MBX Stock Holding History

UBS Group’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1M Sell
272,747
-74,167
-21% -$2.59M ﹤0.01% 2988
2026
Q1 		$10.4M Buy
346,914
+65,702
+23% +$2.23M ﹤0.01% 3304
2025
Q4 		$8.87M Buy
281,212
+220,487
+363% +$5.35M ﹤0.01% 3419
2025
Q3 		$1.06M Buy
60,725
+29,758
+96% +$398K ﹤0.01% 5526
2025
Q2 		$353K Buy
30,967
+3,468
+13% +$35.3K ﹤0.01% 6308
2025
Q1 		$203K Sell
27,499
-18,402
-40% -$195K ﹤0.01% 6547
2024
Q4 		$846K Buy
+45,901
New +$978K ﹤0.01% 5442

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

UBS Group's MBX Position: Q2 2026 in Review

UBS Group reduced its MBX Biosciences (MBX) stake by 21% in Q2 2026, selling an estimated $2.59M and leaving 272,747 shares worth $15.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2988.

UBS Group first reported a position in MBX in Q4 2024 and has held it in 7 quarters since. 172 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • UBS Group held 272,747 shares of MBX Biosciences worth $15.1M as of Q2 2026.
  • UBS Group sold 74,167 MBX Biosciences shares in Q2 2026, an estimated $2.59M.
  • MBX Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2988 holding.
  • UBS Group first reported a position in MBX Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 172 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.